RxSight (RXST) Long-Term Deferred Tax (2022 - 2023)
RxSight's (RXST) quarterly Long-Term Deferred Tax came in at $103.9 million in Q4 2023, up 13.37% on a YoY basis from $91.6 million in Q4 2022, and up 13.37% quarter-over-quarter from $91.6 million in Q4 2022.
Powered by 
Analysis
RxSight (RXST) Long-Term Deferred Tax (2022 - 2023) Analysis & Trends
RxSight (RXST) has reported Long-Term Deferred Tax for 2 consecutive years, with $103.9 million the latest figure, recorded in Q4 2023.
- For the quarter ending Q4 2023, Long-Term Deferred Tax rose 13.37% year-over-year to $103.9 million; the trailing twelve-month figure through Dec 2023 stood at $103.9 million (up 13.37% YoY), and the FY2023 full-year result was $103.9 million, up 13.37% from the prior year.
- Long-Term Deferred Tax climbed to $103.9 million in Q4 2023 per RXST's latest filing, from $91.6 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $103.9 million in Q4 2023 and bottomed at $91.6 million in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn |
| 10 | RxSight | 265.13 Mn | -139.12 Mn | - |